• Find People
  • Campus Map
  • PiratePort
  • A-Z
    • About
    • Submit
    • Browse
    • Login
    View Item 
    •   ScholarShip Home
    • Other Campus Research
    • Open Access
    • View Item
    •   ScholarShip Home
    • Other Campus Research
    • Open Access
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of The ScholarShipCommunities & CollectionsDateAuthorsTitlesSubjectsTypeDate SubmittedThis CollectionDateAuthorsTitlesSubjectsTypeDate Submitted

    My Account

    Login

    Statistics

    View Google Analytics Statistics

    TNM cancer staging: can it help develop a novel staging system for type 2 diabetes?

    Thumbnail
    View/ Open
    TNM_cancer_staging_can_it_hel.pdf (528.3Kb)

    Show full item record
    Author
    Dar, Moahad S.; Bég, Sami A
    Abstract
    Abstract: Type 2 diabetes (DM2) constitutes 90%–95% of the diabetes cases and is increasing at an alarming rate in the world. The Centers for Disease Control and Prevention (CDC) esti- mates that more than 29 million people in the United States have diabetes, which often causes mortality from macrovascular complications and morbidity from microvascular complications. Despite these troubling facts, there is currently no widely accepted staging system for DM2 like there is for cancer. TNM oncologic staging has taken a complex condition like cancer and conveyed likelihood of survival in simple alpha-numeric terms that both patients and providers can understand. Oncology is now entering the era of precision medicine where cancer treatment is increasingly being tailored to each patient’s cancer. In contrast, DM2 lacks a staging system and remains a largely invisible disease even though it kills more Americans and costs more to treat than cancer. Is a comparable staging system for DM2 possible? We propose the Diabetes Staging System for DM2 that utilizes macrovascular events, microvascular complications, estimated glomerular filtration rate (GFR), and hemoglobin A1C to stage DM2.
    URI
    http://hdl.handle.net/10342/8000
    Date
    2018-11-28
    Citation:
    APA:
    Dar, Moahad S., & Bég, Sami A. (November 2018). TNM cancer staging: can it help develop a novel staging system for type 2 diabetes?. , (), - . Retrieved from http://hdl.handle.net/10342/8000

    Display/Hide MLA, Chicago and APA citation formats.

    MLA:
    Dar, Moahad S., and Bég, Sami A. "TNM cancer staging: can it help develop a novel staging system for type 2 diabetes?". . . (), November 2018. September 29, 2023. http://hdl.handle.net/10342/8000.
    Chicago:
    Dar, Moahad S. and Bég, Sami A, "TNM cancer staging: can it help develop a novel staging system for type 2 diabetes?," , no. (November 2018), http://hdl.handle.net/10342/8000 (accessed September 29, 2023).
    AMA:
    Dar, Moahad S., Bég, Sami A. TNM cancer staging: can it help develop a novel staging system for type 2 diabetes?. . November 2018; (): . http://hdl.handle.net/10342/8000. Accessed September 29, 2023.
    Collections
    • Open Access

    xmlui.ArtifactBrowser.ItemViewer.elsevier_entitlement

    East Carolina University has created ScholarShip, a digital archive for the scholarly output of the ECU community.

    • About
    • Contact Us
    • Send Feedback